SOURCE: Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc.

June 18, 2012 12:11 ET

Ohr Pharmaceutical to Present at the 2012 BIO International Convention

NEW YORK, NY--(Marketwire - Jun 18, 2012) - Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that Dr. Irach B. Taraporewala, President and Chief Executive Officer, will present a corporate overview at the 2012 BIO International Convention taking place in Boston, MA from June 18-21, 2012. Dr. Taraporewala's presentation will include an overview of Ohr's Squalamine eye drops for the treatment of wet-AMD, the upcoming phase II clinical trial, and cancer cachexia program along with the Company's business outlook and expected milestones for 2012 through early 2013.

Details of the presentation are as follows:
Presenter: Dr. Irach Taraporewala, President and CEO
Presentation Day: Wednesday, June 20
Time: 3:30 PM
Room: Red Sox Room (104A)

About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical Inc. (OTCBB: OHRP) ( is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds: Squalamine eye drops for the treatment of the wet form of age-related macular degeneration, which has been awarded Fast track designation by the US FDA, and OHR/AVR118 for the treatment of cancer cachexia, currently being investigated in a Phase II trial.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Contact Information